MA29662B1 - Compositions pour l'apport de medicaments hautement solubles dans l'eau - Google Patents

Compositions pour l'apport de medicaments hautement solubles dans l'eau

Info

Publication number
MA29662B1
MA29662B1 MA29665A MA29665A MA29662B1 MA 29662 B1 MA29662 B1 MA 29662B1 MA 29665 A MA29665 A MA 29665A MA 29665 A MA29665 A MA 29665A MA 29662 B1 MA29662 B1 MA 29662B1
Authority
MA
Morocco
Prior art keywords
compositions
delivery
highly water
soluble drugs
drugs
Prior art date
Application number
MA29665A
Other languages
English (en)
Inventor
Andrew Xian Chen
Original Assignee
Sd Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sd Pharmaceuticals Inc filed Critical Sd Pharmaceuticals Inc
Publication of MA29662B1 publication Critical patent/MA29662B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des compositions pour l'apport de médicaments hautement solubles dans l'eau (p. ex. alcaloïdes de la pervenche) et des procédés d'utilisation de ces compositions.
MA29665A 2004-07-12 2007-02-06 Compositions pour l'apport de medicaments hautement solubles dans l'eau MA29662B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/889,226 US7871632B2 (en) 2004-07-12 2004-07-12 Compositions for delivering highly water soluble drugs

Publications (1)

Publication Number Publication Date
MA29662B1 true MA29662B1 (fr) 2008-08-01

Family

ID=35541622

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29665A MA29662B1 (fr) 2004-07-12 2007-02-06 Compositions pour l'apport de medicaments hautement solubles dans l'eau

Country Status (18)

Country Link
US (4) US7871632B2 (fr)
EP (1) EP1773294A4 (fr)
JP (1) JP4643641B2 (fr)
KR (1) KR20070032816A (fr)
CN (1) CN1859898B (fr)
AU (1) AU2005271873A1 (fr)
BR (1) BRPI0513178A (fr)
CA (1) CA2578574C (fr)
EA (1) EA012522B1 (fr)
EC (1) ECSP077238A (fr)
IL (1) IL180350A0 (fr)
MA (1) MA29662B1 (fr)
MX (1) MX2007000416A (fr)
NO (1) NO20070785L (fr)
RS (1) RS20070029A (fr)
TW (1) TW200607525A (fr)
WO (1) WO2006017246A2 (fr)
ZA (1) ZA200701167B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2007107359A (ru) * 2004-07-28 2008-09-10 ЭсДи ФАРМАСЬЮТИКАЛЗ, ИНК. (US) Стабильная инъецируемая композиция альфа-токоферилсукцината, его аналогов и солей
US8557861B2 (en) * 2004-09-28 2013-10-15 Mast Therapeutics, Inc. Low oil emulsion compositions for delivering taxoids and other insoluble drugs
CN101011355B (zh) * 2006-02-01 2013-01-02 陈献 经维生素e琥珀酸酯稳定的医药组合物、其制备及用途
TWI376239B (en) * 2006-02-01 2012-11-11 Andrew Xian Chen Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
CA2651988A1 (fr) * 2006-05-12 2007-11-22 Adventrx Pharmaceuticals, Inc. Compositions pharmaceutiques pour medicaments irritants pour les veines
WO2009078754A1 (fr) 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Système d'administration de médicament permettant d'administrer des substances pharmaceutiquement actives faiblement hydrosolubles
WO2009078756A1 (fr) * 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Système d'administration de médicament pour administrer une substance pharmaceutiquement acceptable amphiphile, cationique et hydrosoluble
US8618056B2 (en) * 2007-12-22 2013-12-31 Cuthbert O. Simpkins Methods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries
US8063020B2 (en) * 2007-12-22 2011-11-22 Simpkins Cuthbert O Resuscitation fluid
US8906855B2 (en) * 2007-12-22 2014-12-09 Vivacelle Bio, Inc. Methods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries
JP2011514337A (ja) * 2008-02-25 2011-05-06 ノババックス，インコーポレイテッド 糖ガラス化ウィルス様粒子（ｖｌｐ）
US20090286832A1 (en) * 2008-05-15 2009-11-19 Kiichiro Nabeta Narcotic emulsion formulations for treatment of surgical pain
EA201190135A1 (ru) * 2009-02-26 2012-07-30 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Композиции на основе эмульгированных наркотических веществ для лечения боли при раке
CN101879138A (zh) 2009-05-06 2010-11-10 上海恒瑞医药有限公司 长春花生物碱纳米乳剂注射液及其制备方法
CN102573475B (zh) 2009-08-14 2016-01-20 欧科生医股份有限公司 神经激肽-1拮抗剂的静脉内制剂
JP5877843B2 (ja) * 2010-10-22 2016-03-08 ドクター レディズ ラボラトリーズ， インコーポレイテッド 創傷を処置するための保存に安定した粘性リン脂質デポーの使用
WO2012135856A2 (fr) * 2011-04-01 2012-10-04 Spectrum Pharmaceuticals, Inc. Vinorelbine à très faible dose pour le traitement du cancer
CN102743337B (zh) * 2011-04-20 2014-04-16 国家纳米科学中心 一种纳米粒子药物组合物及其制备方法
CN103826609A (zh) * 2011-06-09 2014-05-28 安米林药品有限责任公司 凝胶组合物
EP3069785A1 (fr) 2011-10-25 2016-09-21 The University Of British Columbia Nanoparticules lipides de taille limite, et procédés correspondants
CA2871821C (fr) 2012-05-10 2021-01-12 Painreform Ltd. Preparations de depot d'un anesthesiant local et procedes de preparation associes
CN105143456A (zh) 2013-03-15 2015-12-09 不列颠哥伦比亚大学 用于转染的脂质纳米粒子和相关方法
US20140275261A1 (en) 2013-03-15 2014-09-18 Dr. Reddy's Laboratories, Inc. Diclofenac parenteral compositions
US20160290093A1 (en) * 2015-04-02 2016-10-06 Baker Hughes Incorporated Disintegrating Compression Set Plug with Short Mandrel
JP6951825B2 (ja) 2015-09-04 2021-10-20 ザ スクリプス リサーチ インスティテュート インスリン免疫グロブリン融合タンパク質
KR20230110283A (ko) * 2020-11-19 2023-07-21 니폰 카야쿠 가부시키가이샤 혈관 장애를 유발하는 수용성 의약 함유 조성물, 혈관 장애를 유발하는 수용성 의약 함유 투여액 조제용 용액, 키트, 혈관 장애 억제제 및 비이온계 계면활성제 함유 용액
US12419850B1 (en) 2024-03-21 2025-09-23 GanD, Inc. Bioactive fluid compositions

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US224042A (en) * 1880-02-03 Music-rest for piano-fortes
US670001A (en) * 1900-02-15 1901-03-19 Stephen B Morss Combined curb and gutter.
US4816247A (en) * 1985-09-11 1989-03-28 American Cyanamid Company Emulsion compositions for administration of sparingly water soluble ionizable hydrophobic drugs
IL88076A (en) * 1987-10-28 1993-01-14 Nippon Shinyaku Co Ltd Fat emulsions as drug carriers
NZ233827A (en) 1989-05-26 1991-06-25 Abbott Lab Pharmaceutical composition comprising clarithromycin, triglyceride oil and stabilising agent
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5576016A (en) * 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
US5977172A (en) * 1995-09-13 1999-11-02 Nippon Shinyaku Co., Ltd. PGE1 -containing-freeze dried preparation and process for the production thereof
JP2001503735A (ja) * 1996-07-03 2001-03-21 ユニバーシティ オブ ピッツバーグ 親水性活性試薬のためのエマルジョン処方物
TR200202738T2 (tr) * 1997-04-28 2003-03-21 Texas Biotechnology Corporation Endotelin ile ilgili hastalıkların tedavisinde kullanılan sülfanoamidler
US6723338B1 (en) * 1999-04-01 2004-04-20 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
GB9925127D0 (en) 1999-10-22 1999-12-22 Pharmacia & Upjohn Spa Oral formulations for anti-tumor compounds
US6136846A (en) * 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
JP2003277281A (ja) * 2002-03-20 2003-10-02 Kumamoto Technology & Industry Foundation 静脈炎の予防及び治療のための医薬
US6890558B2 (en) 2002-05-31 2005-05-10 R.P. Scherer Technologies, Inc. Oral pharmaceutical composition for soft capsules containing vinorelbine and method of treatment
JP4426749B2 (ja) * 2002-07-11 2010-03-03 株式会社産学連携機構九州 Ｏ／ｗ型エマルション製剤
US20050049209A1 (en) * 2003-08-06 2005-03-03 Chen Andrew Xian Pharmaceutical compositions for delivering macrolides
RU2007107359A (ru) * 2004-07-28 2008-09-10 ЭсДи ФАРМАСЬЮТИКАЛЗ, ИНК. (US) Стабильная инъецируемая композиция альфа-токоферилсукцината, его аналогов и солей
CN1634058A (zh) * 2004-10-20 2005-07-06 李晓祥 长春瑞滨乳剂及其制备方法

Also Published As

Publication number Publication date
US8026250B2 (en) 2011-09-27
ECSP077238A (es) 2007-04-26
AU2005271873A1 (en) 2006-02-16
NO20070785L (no) 2007-04-02
EP1773294A4 (fr) 2012-11-21
US20120046310A1 (en) 2012-02-23
JP4643641B2 (ja) 2011-03-02
CA2578574A1 (fr) 2006-02-16
US20060008480A1 (en) 2006-01-12
HK1100062A1 (en) 2007-09-07
JP2008505972A (ja) 2008-02-28
KR20070032816A (ko) 2007-03-22
US7871632B2 (en) 2011-01-18
CN1859898A (zh) 2006-11-08
CA2578574C (fr) 2013-09-10
TW200607525A (en) 2006-03-01
US20130029918A1 (en) 2013-01-31
IL180350A0 (en) 2007-06-03
BRPI0513178A (pt) 2008-04-29
RS20070029A (sr) 2008-11-28
ZA200701167B (en) 2010-08-25
EA200700312A1 (ru) 2007-08-31
EA012522B1 (ru) 2009-10-30
WO2006017246A3 (fr) 2006-03-30
US20110082168A1 (en) 2011-04-07
EP1773294A2 (fr) 2007-04-18
US8222268B2 (en) 2012-07-17
CN1859898B (zh) 2011-06-08
WO2006017246A2 (fr) 2006-02-16
MX2007000416A (es) 2007-03-28

Similar Documents

Publication Publication Date Title
MA29662B1 (fr) Compositions pour l'apport de medicaments hautement solubles dans l'eau
WO2007149406A8 (fr) Polypeptides facteurs ix de la coagulation modifiés et leur utilisation thérapeutique
WO2002070438A3 (fr) Compositions permettant l'administration de biophosphonates
EP1858926A4 (fr) Glycosaminoglycanases solubles et procédés de préparation et d'utilisation de glycosaminoglycanases solubles
WO2006060547A3 (fr) Systemes et methodes d'administration intra-orale de medicaments
IS6994A (is) Arípíprazóllausn til gjafar um munn
TW200635897A (en) Piperidine derivatives and their use as anti-inflammatory agents
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
FR2851470B1 (fr) Composition pharmaceutique pour administration transdermique ou transmuqueuse
WO2005115398A3 (fr) Inhibiteurs d'integrase de vih
WO2005112633A3 (fr) Composes et compositions pour administration d’agents actifs
WO2005102392A3 (fr) Methodes de traitement d'une infection a vih
IL176519A0 (en) Directly compressible pharmaceutical composition for the oral administration of cci-779
WO2007025005A3 (fr) Formulations de nalbuphine a liberation prolongee
TW200626132A (en) Topical nepafenac formulations
DK1551803T3 (da) Azabicycloderivater som muskarine receptorantagonister
WO2004093805A3 (fr) Modulateurs des recepteurs aux glucocorticoides spirocycliques selectifs
IS8051A (is) Kladríbínefnablöndur til inngjafar um munn
WO2003041656A3 (fr) Systeme de liberation prolongee de medicaments solubles
NO20064808L (no) Orale matrixformuleringer med licarbazepin
TW200503783A (en) Oral pharmaceutical preparation for proton pump antagonists
NO20064783L (no) Opplosningstabeletter med licarbazepin
WO2006064228A3 (fr) Composes
WO2005062874A3 (fr) Composes et compositions pour l'administration d'agents actifs